PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/167706

Please be advised that this information was generated on 2021-04-27 and may be subject to change.
A genome-wide association study in multiple system atrophy

ABSTRACT

Objective: To identify genetic variants that play a role in the pathogenesis of multiple system atrophy (MSA), we undertook a genome-wide association study (GWAS).

Methods: We performed a GWAS with >5 million genotyped and imputed single nucleotide polymorphisms (SNPs) in 918 patients with MSA of European ancestry and 3,864 controls. MSA cases were collected from North American and European centers, one third of which were neuro-pathologically confirmed.

Results: We found no significant loci after stringent multiple testing correction. A number of regions emerged as potentially interesting for follow-up at p < 1 × 10^−6, including SNPs in the genes FBXO47, ELOVL7, EDN1, and MAPT. Contrary to previous reports, we found no association of the genes SNCA and COQ2 with MSA.

Conclusions: We present a GWAS in MSA. We have identified several potentially interesting gene loci, including the MAPT locus, whose significance will have to be evaluated in a larger sample set. Common genetic variation in SNCA and COQ2 does not seem to be associated with MSA. In the future, additional samples of well-characterized patients with MSA will need to be collected to perform a larger MSA GWAS, but this initial study forms the basis for these next steps. Neurology® 2016;87:1591-1598

GLOSSARY

GWAS = genome-wide association study; MAF = minor allele frequency; MSA = multiple system atrophy; OR = odds ratio; PD = Parkinson disease; SNP = single nucleotide polymorphism.

Multiple system atrophy (MSA) is an adult-onset neurodegenerative disorder of unknown cause. Clinical features include parkinsonism, cerebellar ataxia, pyramidal signs, and dysautonomia. MSA typically presents as a sporadic disease, although rare reports of familial occurrences have been described,1–3 and there is a greater risk of parkinsonian disorders in relatives of patients with MSA.4 The pathogenesis of MSA is largely unknown. Identification of α-synuclein-positive glial cytoplasmic inclusions as a neuropathologic hallmark provided the first clue that abnormal protein accumulation is involved in the development of MSA.5 Furthermore, it suggested a link to other neurodegenerative diseases that are characterized by α-synuclein deposition, commonly referred to as synucleinopathies. These include Parkinson disease (PD), MSA, dementia with Lewy bodies, pure autonomic failure, and neurodegeneration with brain iron accumulation type 1.6 Additional evidence in support of shared pathogenic mechanisms among synucleinopathies was suggested by recent genetic findings demonstrating that variants at the SNCA locus, coding for the deposited α-synuclein protein, are associated with increased risk for PD and MSA.7,8 In addition, the (MAPT) H1 haplotype has been associated with MSA.7,9 More recently, the COQ2 gene was reported to harbor mutations in familial MSA cases from Japan.10 However, follow-up studies in non-Asian ethnic cohorts were unable to replicate this finding.11,12 Thus, many prior observations require further evaluation.

© 2016 American Academy of Neurology

© 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
To investigate whether common genetic risk factors play a role in MSA, we performed a genome-wide association study (GWAS) including 918 patients with MSA and 3,864 controls.

**METHODS** Study design. We performed a multicenter GWAS with patients with MSA of European ancestry and regionally matched controls. Collection sites for this study included brain banks and clinical centers in Germany, Austria, Netherlands, Denmark, the United Kingdom, Italy, Portugal, Spain, and the United States (table e-1 at Neurology.org). Since patients were recruited in different geographic regions across Europe and the United States, we matched cases with regional controls. Genotype data of healthy individuals from previous GWAS were obtained from Germany, the United Kingdom, the United States, and Italy. The MSA cases were grouped into 4 geographic regions and each case was matched with 4 controls from the same geographic region: UK and Irish MSA cases were matched with UK controls; Northern European MSA cases from Germany, Netherlands, Belgium, Austria, Denmark, and Sweden were matched with German controls; Southern European cases from Italy and Spain were matched with Italian controls; American MSA cases were matched with American controls. Matching was carried out using multidimensional scaling based on the first 2-component vectors for each subpopulation, derived from common variants assayed in both cases and controls (minor allele frequency [MAF] > 0.05). A flowchart of studied populations and quality control steps is shown in figure e-1.

**Study participants.** DNA samples from a total of 1,030 patients with MSA were collected for this study (details for each population are shown in table 1, demographics are listed in table e-2). Patients were clinically diagnosed with possible or probable MSA (n = 699) by movement disorders specialists, or pathologically with definite MSA (n = 331) by neuropathologists according to Gilman criteria. For controls, we used genotype data from 3,864 previously published neurologically normal individuals from the United Kingdom (n = 936 samples), Germany (n = 944 samples), United States (n = 794 samples), and Italy (n = 1,190 samples) (table 1). All controls were genotyped on Illumina Bead-Chips (Illumina, San Diego, CA, USA). Details about sample collection and genotyping procedures in control cohorts have been described elsewhere.

**Standard protocol approvals, registrations, and patient consents.** The appropriate institutional review boards approved the study, and written informed consent was obtained for each participant.

**Genotyping.** Samples from 1,030 MSA cases were genotyped on 1 of 3 Illumina genotyping BeadChips (Human610-Qud v1, Human600W-Qud v1, or HumanOmniExpress-12 v3). Control samples were genotyped on the following BeadChips: UK WTCCC on Illumina Human1.2M-DuoCustom BeadChip; US, German, and Italian controls on Illumina BeadChips 550K version 1 chips or version 3.7,4,16 These chip versions have 343,783 unique single nucleotide polymorphisms (SNPs) in common, and only shared SNPs were used for downstream analyses.

**Statistical analysis.** **Genotype calling.** For each of the 3 genotyping platforms, raw data were imported to GenomeStudio (v2010.1, genotyping module v1.6.3, Illumina) and genotype calls were reclustered using a no-call threshold of <0.15.

**Quality control.** For quality control, we excluded samples with a genotyping call rate <95%, duplicate samples, cryptically related individuals (pi-hat threshold >0.2), individuals in whom the reported sex did not match the genotypic sex, and individuals with non-European ancestry as determined by multiple dimensional scaling analysis (samples deviating >6 SDs from the CEU/TSI population were excluded; see figure e-2). Next, we excluded SNPs with inaccurate cluster separation (cluster separation score >95%), SNPs that were not shared among all 3 genotyping chip versions, and SNPs with an individual SNP call rate <95%. Following this step, we excluded SNPs with missingness by haplotype or phenotype that exceeded a significance of p value < 0.00001 or a significant deviation from Hardy-Weinberg equilibrium with a p value < 0.0001. Of the remaining SNPs, only those with a MAF > 0.01 were used for downstream analyses.

**Power calculations and heritability analysis.** Power calculations were performed for a GWAS testing 918 cases and 3,864 controls under a log-additive and a recessive model (QUANTO software v1.2.3). A minor allele frequency >1% and a 2-sided α = 5 × 10⁻⁶ were assumed. Under the log-additive model (figure e-3A), power analysis for this study indicated greater than 80% power to detect associated loci with an odds ratio greater than 1.8 at risk allele frequencies between 7% and 87%. We recently also performed a heritability analysis based on our GWAS data demonstrating that the heritability for MSA due to common coding variants is estimated to be between 2.1% and 6.7%.

**Genotype imputation.** About 4,903,804 SNPs were imputed based on haplotype reference data from the 1000 Genomes project (1000genomes.org; December 2010 version). These data were derived from studying the genomic sequence of 104 participants of European ancestry. Imputations were performed for each of the 4 cohorts separately using MACH software as described elsewhere (version 1.0.16,18,19 SNPs with an MAF <0.3 and MAF < 0.01 were excluded from further analysis as imputed genotypes below this threshold are likely to be of poor quality.

**Association tests.** Due to the relatively diverse ancestries of European and US cohorts included in this study, we used principal component vectors 1 to 10 from a multidimensional scaling analysis generated in PLINK as covariates to adjust for possible population substructure in the logistic regression model used for the GWAS (figure e-4). The genomic inflation factor was 1.000.
uncut. Disease association was tested with a product. The major allele was cut, whereas the minor allele remained (New England Biolabs, Ipswich, MA) was used to cut the PCR amplify the SNP and surrounding region. Restriction enzyme Bsr1 genotyped using a restriction enzyme assay. Primers were designed to

\[
\text{Mb from each SNP) in each of the datasets.}^21
\]

SNP rs11931074, located downstream of the gene, was re-genotyped using a restriction enzyme assay. Primers were designed to amplify the SNP and surrounding region. Restriction enzyme Bsr1 (New England Biolabs, Ipswich, MA) was used to cut the PCR product. The major allele was cut, whereas the minor allele remained uncut. Disease association was tested with a \( \chi^2 \) test.

**Analysis of brain tissue quantitative trait loci.** For SNPs of interest, we attempted to infer functional consequences in frontal cortex and cerebellar tissue samples from neurologically normal individuals that were assayed for both genome-wide methylation and expression levels.\(^{20}\) These analyses may shed light on potential disease mechanisms for follow-up in future studies. We tested \( \textit{cis} \) associations (any methylation or expression probes \( \pm 1 \text{Mb from each SNP} \) in each of the datasets).\(^{21}\)

**RESULTS** Genotyping, imputation, and quality control. After quality control procedures, the total study consisted of 918 cases and 3,864 controls. Of the MSA cases, 291 had a pathologically confirmed diagnosis. Samples were successfully genotyped for 267,998 SNPs and imputed to 4,903,804 SNPs. After removal of extreme ancestry outliers and using multidimensional scaling component vectors as covariates in regression models, only mild population stratification was evident based on genomic inflation factor calculations \( (\lambda = 1.057) \) (figure e-2).

**Association results.** Statistical analysis of association under an additive model was performed in the full case-control dataset (figure 1) and in the subset of MSA cases with neuropathologically confirmed diagnosis. Loci with the lowest \( p \) values \( (\leq 1 \times 10^{-6}) \) in the full dataset and pathology confirmed cases are shown in tables 2 and e-3, respectively. In the full dataset, we identified 4 loci for future follow-up in a larger sample series at a \( p \) value \( < 1 \times 10^{-7} \) including the genes \( \text{FBXO47}, \text{ELOVL7}, \text{EDN1}, \) and \( \text{MAPT} \). None of the tested SNPs surpassed the Bonferroni threshold for multiple testing \( (p \text{ value} < 5 \times 10^{-8}) \) in the full dataset or in the subanalysis of pathologically confirmed cases.

**COQ2 in the MSA GWAS data.** Recently, homozygous (or compound heterozygous) mutations in \( \text{COQ2} \) were reported in familial cases of MSA in Japan.\(^9\) While coding variants were also found at a higher frequency in sporadic MSA compared to controls, this finding did not replicate outside of Japanese MSA samples. We investigated the \( \text{COQ2} \) locus for common variation in our GWAS data. A total of 453 SNPs in the \( \text{COQ2} \) gene and the flanking region \( \pm 100 \text{kb} \) (build 36,3 positions) were tested for association. The most associated SNP was chr4:84473327 with a \( p \) value of 0.02169, which is far from genome-wide or even regional Bonferroni-adjusted significance. We therefore lack evidence that common genetic variation in the \( \text{COQ2} \) locus plays a major role in MSA risk in the European/Northern American population.

**SNCA rs11931074 SNP genotyping.** SNP rs11931074 in the \( \text{SNCA} \) locus (or rs3822086, which is in close linkage disequilibrium) has been linked to MSA in several smaller studies.\(^{8,22,23}\) This SNP is not represented on the OmniExpress Bead arrays; hence, it was not genotyped in any samples run on this array \( (n = 703) \) and consequently was not in the dataset of genotyped SNPs in common. Instead, the allele frequency was calculated postimputation, demonstrating that it was neither significantly associated in the entire dataset \( (p \text{ value} = 0.4722) \) nor in the subgroup of definite MSA cases \( (p \text{ value} = 0.4407) \). We

---

**Figure 1** Manhattan plot showing association results in multiple system atrophy

\[ p \text{ Values under the additive association model are log transformed (y-axis) and plotted against the chromosomal position (x-axis). The dotted line indicates the threshold of potentially interesting single nucleotide polymorphisms.} \]
Results for association tests in multiple system atrophy cases vs controls are shown.

MAPT

First allele refers to effect allele.

Abbreviations: OR = odds ratio; UTR = untranslated region.

Results for association tests in multiple system atrophy cases vs controls are shown.

aFirst allele refers to effect allele.

MAPT is not the closest gene in this locus but due to its known role in other neurodegenerative diseases the most likely candidate.

decided to regenotype SNP rs11931074 in the MSA GWAS cohort using a restriction enzyme to exclude technical or imputation uncertainty (despite a high imputation score of 0.9670). Within the GWAS cohort, 906 MSA samples were available for regenotyping (table 3).

In controls, data for this SNP were available from the bead array data. The minor allele of SNP rs11931074 was slightly more common in MSA cases vs controls (8.3% vs 7.3%) but again no significant association was found with MSA ($\chi^2 = 2.6; p$ value = 0.27). This is in concordance with the imputed GWAS finding, but contradicts previous reports in the literature.8,22,23

Analysis of brain tissue quantitative trait loci in candidate loci. Twenty-one out of 24 SNPs of interest ($p$ value < $1 \times 10^{-5}$) passed quality control in the mRNA expression datasets, and 23 SNPs of interest passed quality control in the CpG methylation datasets. We tested multiple probes per SNP in each set of analyses. A total of 168 unique SNP–probe pairs were tested in the frontal cortex mRNA expression dataset, 165 pairs in the cerebellar mRNA expression dataset, and 391 pairs in the frontal cortex and cerebellar CpG methylation dataset. Associations were tested using linear regression adjusting for appropriate covariates and resulting $p$ values were adjusted based on the false-discovery rate correction as previously described.21

After correcting for multiple testing, we found 8 significant associations between SNPs of interest and either CpG methylation or mRNA expression.

### Table 2 Summary of loci with a $p$ value below 1E-6

| Chromosome | Position   | Marker       | Nearest gene | Location | Putative function                                      | p Value | OR    | Alleles | Allele frequency | $R^2$ |
|------------|------------|--------------|--------------|----------|--------------------------------------------------------|---------|-------|---------|-----------------|-------|
| 17         | 34,359,508 | rs78523330   | FBXO47       | Intron   | Involved in protein ubiquitination and degradation     | 1.84E-07| 0.45  | A/G    | 0.96            | 0.55  |
| 5          | 60,088,977 | rs7751514    | ELOVL7       | Intron   | Lipid metabolism                                      | 2.87E-07| 1.47  | C/A    | 0.74            | 0.68  |
| 6          | 12,453,679 | rs16872704   | EDN1         | Intergenic| Vasoconstrictor                                       | 3.82E-07| 1.51  | A/G    | 0.84            | 0.94  |
| 17         | 41,160,977 | rs9303521    | CRHR1        | Intron   | G-protein coupled receptor, activation of signal transduction pathways | 6.78E-07| 0.76  | T/G    | 0.51            | 0.92  |
| 17         | 4,023,064  | rs12044274   | LOC728716    | Intergenic| Noncoding RNA                                         | 3.30E-06| 1.48  | T/A    | 0.65            | 0.47  |
| 6          | 7,161,483  | rs1413700    | RREB1        | Intron   | Zinc finger transcription factor                      | 3.43E-06| 1.39  | G/C    | 0.79            | 0.92  |
| 2          | 239,000,140| rs473651     | ASB1         | Intergenic| Testis development                                    | 3.54E-06| 0.78  | C/A    | 0.62            | 0.98  |
| 17         | 42,218,292 | rs916888     | WNT3         | Intergenic| WNT signaling gene, embryogenesis                     | 3.68E-06| 1.35  | T/C    | 0.75            | 0.96  |
| 14         | 47,000,222 | rs78274439   | MDGA2        | Intron   | Possibly involved in cell-cell interactions           | 3.73E-06| 1.73  | A/G    | 0.85            | 0.46  |
| 20         | 59,576,381 | rs2252187    | CDH4         | Intron   | Calcium-dependent cell adhesion                       | 3.97E-06| 0.74  | G/A    | 0.77            | 0.81  |
| 10         | 100,039,469| rs4919206    | LOXL4        | Intergenic| Biogenesis of connective tissue                       | 4.36E-06| 0.73  | C/G    | 0.49            | 0.58  |
| 17         | 14,628,830 | rs62060075   | CDRT7        | Intergenic| Noncoding RNA                                         | 4.64E-06| 0.60  | C/T    | 0.92            | 0.61  |
| 8          | 28,005,267 | rs4872401    | EBFB2        | Intergenic| Transcription factor                                  | 4.75E-06| 0.38  | G/A    | 0.96            | 0.33  |
| 5          | 40,890,439 | rs1697938    | CARD6        | UTR      | Involved in apoptosis                                 | 4.75E-06| 0.79  | T/C    | 0.54            | 0.99  |
| 16         | 22,938,761 | rs8044188    | USP31        | Intergenic| Unknown                                                | 4.84E-06| 1.38  | G/A    | 0.79            | 0.95  |
| 12         | 148,443,344| rs10819190   | LMX1B        | Intergenic| Transcription factor                                  | 5.41E-06| 1.32  | G/A    | 0.63            | 0.82  |
| 5          | 127,863,758| rs892864     | FBN2         | Intron   | Component of connective tissue microfibrils           | 5.96E-06| 1.62  | T/A    | 0.06            | 0.81  |
| 2          | 31,430,416 | rs115903524  | XDH          | Intron   | Purine degradation                                    | 6.41E-06| 0.51  | G/C    | 0.97            | 0.83  |
| 19         | 33,413,730 | rs11084877   | LOC148189    | Intergenic| Noncoding RNA                                         | 6.65E-06| 0.76  | A/G    | 0.76            | 0.96  |
| 2          | 138,023,816| rs10209086   | THSD7B       | Intron   | Unknown                                                | 6.95E-06| 0.78  | T/C    | 0.42            | 0.98  |
| 9          | 85,989,249 | rs2256039    | SLC28A3      | Intergenic| Nucleoside transporter                                 | 7.92E-06| 0.70  | A/C    | 0.86            | 0.74  |
| 16         | 85,251,338 | rs78765336   | FOXL1        | Intergenic| Unknown                                                | 8.46E-06| 0.46  | G/T    | 0.97            | 0.57  |
| 7          | 24,585,776 | rs55782418   | MMP6         | Intergenic| Tumor suppression and receptor clustering             | 9.59E-06| 0.58  | G/C    | 0.96            | 0.90  |
| 17         | 51,515,165 | rs79331640   | ANKFN1       | Intergenic| Unknown                                                | 9.97E-06| 0.45  | G/A    | 0.97            | 0.54  |
Among the most highly associated regions is the MAPT locus. MAPT is an intriguing candidate as it has already been implicated in a number of neurodegenerative diseases, particularly in tauopathies such as progressive supranuclear palsy, frontotemporal degeneration, and Alzheimer dementia. Although tau is not considered a key protein in MSA neuropathology, PD—which is also an α-synucleinopathy—has been found to be consistently associated with common variation in the MAPT locus. Furthermore, MSA was also previously found to be associated with the MAPT H1 haplotype in a small cohort of American MSA cases. These results, however, will need to be verified in a larger MSA cohort.

Located on chromosome 6, EDN1 is part of the endothelin gene family, which functions in the maintenance of vascular tone. Studies have demonstrated the presence of endothelin peptides in nonvascular structures including epithelial cells, glia, and neurons. Given the phenotype of autonomic dysfunction or failure in patients with MSA, one may hypothesize that such pathophysiology may be associated with variation in EDN1. ELOVL7, originating on chromosome 5, is involved in transferase activity. Chiefly, transferase is a condensing enzyme that acts as a catalyst for the synthesis of saturated and polyunsaturated very long chain fatty acids.

FBXO47 has a known association with papillary renal cell carcinoma. Located on chromosome 17, FBXO47 promotes protein ubiquitination and degradation via phosphorylation, which are critical mechanisms in many neurodegenerative diseases. This locus could provide an important mechanism to MSA pathology in light of the oligodendroglial α-synuclein burden, but requires further study to draw any conclusions.

Common variation in the COQ2 gene (recently found to be mutated in familial and sporadic probable MSA cases in Japan) did not show a significant association in the MSA GWAS data. This suggests that common genetic variation in this gene does not play a major role in disease pathogenesis in patients with MSA of European descent.

We were unable to replicate the previously reported association of variants at the SNCA. A Korean study was also unable to reproduce the association indicating possible differences between populations or an actual null result. The previously associated SNP rs11931074 has considerable variation in frequency among different populations. The reported risk allele has a frequency of about 7%–8% in our different European controls and in the European HapMap data. In contrast, the same allele is much more abundant in Asian and African populations (e.g., 58% in Japanese and 68% in Yorubans). Our study attempts to account for both interpopulation and intrapopulation heterogeneity through principal component analysis, and interpopulation heterogeneity of SNCA is a plausible explanation for the previous findings.

The quantitative trait analysis data suggest a complex risk locus on chromosome 17. This includes several SNPs in the region associated with multiple expression or methylation effects. Several of these genes are involved in pathways potentially relevant to MSA pathology: namely, the ribosylation protein (ARL17A), the ribosome protein (RPL19), and the proteasome protein (PSMB3).

The disease pathology of several neurodegenerative disorders illustrates a common theme of disrupted proteasomal protein clearance and degradation. Notably, PSMB3 may be involved in trinucleotide repeat expansion—a phenomenon seen in several

### Table 3

| SNP          | Restriction enzyme digest result | p Value     |
|--------------|---------------------------------|-------------|
| rs11931074   | 906                             | 0.0738      |
| TT           | 7                               | 0.2725      |
| TG           | 133                             | 0.0835      |
| GG           | 740                             | 0.0738      |
| MAF MSA      | 0.0835                          |             |
| MAF control  | 0.0738                          |             |
| x²           | 2.6                             |             |

Abbreviations: MAF = minor allele frequency, MSA = multiple system atrophy.
hereditary neurologic disorders (in particular autosomal dominant ataxias)—and it may be driving the trinucleotide expansion process. Supporting this hypothesis, there is considerable clinical overlap between MSA and several hereditary ataxias.35,36 Similarly, ribosomal dysfunction with aberrant protein synthesis may promote neurodegeneration.37 Interestingly, no alteration in expression of MAPT—the most obvious candidate gene in the chromosome 17 locus—was found. All but one associated QTL in MSA were found in cerebellar tissue (table e-4). Since the cerebellum is among the most disturbed brain regions in MSA, differences in expression in this region are consistent with an etiologic role in MSA.

There are a number of limitations to this study. First, although this represents by far the largest collection of MSA samples to date, the number of MSA cases is still relatively small for a GWAS. GWAS are designed to identify disease variants of relatively high frequency (MAF >1%) in a population operating under the common disease/common variant hypothesis.38 In PD, most identified risk factors have an odds ratio (OR) between 0.8 and 1.5.39 Similarly, in Alzheimer disease—apart from APOE (OR ~4)—common genetic risk factors have low ORs ranging from 0.8 to 1.2. In these diseases, successful identification of significant loci was only feasible with considerably larger sample sizes than our study. However, with our current number we can reasonably exclude the existence of common risk alleles of large effect. A second limitation is the use of population control cohorts rather than age-matched controls, which increases the chance for population heterogeneity. We applied stringent corrections, including principal components from multidimensional scaling as covariates in our statistical model to address this concern. Third, the misdiagnosis rate of clinically ascertained patients, in particular those in early disease stages, can be as high as 38%.40 We addressed this concern by including a large number of pathology-proven cases (~one-third of all patients in this study). The inclusion of pathology-confirmed cases is particularly important for future follow-up studies in MSA.

Finally, a major challenge is that currently no additional large cohorts of MSA cases with a similar genetic background are available. A comparison of European and non-European cohorts may be informative with regard to population heterogeneity.

None of the studied variants were statistically significant after appropriate correction for multiple testing. However, we identified 4 promising loci that could reveal important insight into the disease pathways of MSA. Increasing the sample size of our GWAS will be key to the successful confirmation of these candidate loci and the identification of other risk genes.

AUTHOR AFFILIATIONS
From the Departments of Molecular Neuroscience and Movement Disorders and The Reta Lila Weston Institute (A.S., A.L., W.P., W.O., U.W., N.Q., H.W., A.A., J.I., K.B., R.B.), Department of Neurology (G.U.H.), Technische Universität München, Concrete Center for Neurodegenerative Diseases (DZNE) (G.U.H., W.G.M.), the UK Parkinson's Disease Society Brain Tissue Bank at Imperial College (London, UK), the Institute of Psychiatry Brain Bank, King's College (London), UK, the UK Parkinson's disease tissue bank at Imperial College (London, UK), and the Institute of Neurology, London, UK, Klinik für Neurologie (A.S.), Universitätsgesellschaft der Johann-Wolfgang-Goethe Universität Frankfurt, Germany; Laboratory of Neurogenetics, National Institute on Aging (S.W.S., M.A.N., M.F., T.R.P., B.J.T., A.B.S.), and Neurodegenerative Diseases Research Unit, National Institute of Neurological Disorders and Stroke (S.W.S.), National Institutes of Health, Bethesda, MD, Department of Neuroscience (S.W.S.), Georgetown University, Washington, DC, Department of Neurology (G.D.), UKSH, Kiel Campus, Christian-Albrechts University Kiel, Germany; Division of Neurology (H.W.), Department of Clinical Sciences, University Hospital Lund, Sweden; Istituto Clinico Humanitas (A.A.), Università Cattolica del Sacro Cuore, Milan, Italy; Service of Neurology (F.I.), University Hospital Manquis de Valdecilla (IDIVAL), University of Cantabria (UC), Santander, Spain; Institute of Neurology (G.W.K.), Medical University Innsbruck, Austria; Centre de Nervous Diseases (W.O.), Philippus-University of Marburg; Department of Neurology (G.U.H.), Technische Universität München; German Center for Neurodegenerative Diseases (DZNE) (G.U.H., W.G.M.), Munich; Department of Neurology (U.W.) and German Center for Neurodegenerative Diseases (U.W.), University Hospital of Bonn Medical Center, Germany; Parkinson Institute (S.G.), Institute Clinico di Periferizzazione, Milan; Center for Neurodegenerative Diseases (M.T.P.), Department of Medicine and Surgery, Neuroscience Section, University of Salerno, Italy; Clinical Pharmacological Unit (J.F.), Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Portugal; Hospital Clinic (E.T.), University of Barcelona, Spain; Department of Neurology (B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, Netherlands; Clinical Investigation Center CIC3436 (O.R.), Departments of Clinical Pharmacology and Neurosciences, INSERM and University Hospital of Toulouse, Faculty of Medicine; Centre de Référence Atrophie Multisystématisée (W.G.M.), CHU de Bordeaux, Pessac; and Université de Bordeaux (W.G.M.), Institut des Maladies Neuродégnératives, UMR 5293, Bordeaux, France.

AUTHOR CONTRIBUTIONS
Patient recruitment: H.H., A.S., N.W., G.K.W., A.L., W.P., W.O., U.W., S.G., M.T.P., T.G., C.S., D.H.D., S.O., A.L., L.F., M.H., G.D., N.Q., H.W., A.A., J.I., K.B., R.B., W.P., G.U.H., U.W., S.G., M.T.P., J.F., E.T., B.B., J.A.H., T.R., J.H., D.B., V.K., P.C., H.R., J.S., A.S., E.R., G.M., C.C., P.B., L.D.T., O.R., R.D., T.G., A.A., W.M., K.O., E.D., N.P., M.J.L., I.S., G.C.B., S.C., L.S., T.K., F.T., A.F., S.A.S., A.L., R.P., C.N., O.H., V.R., F.D., H.B., J.K., A.R., C.P., G.F., F.D., M.S., M.I.P., A.P., M.S., D.B., O.R., N.R., N.G., Y.B., H.S., Y.M., M.P., and R.B. Sample preparations: A.S., J.L.H., T.R., S.W.S., C.S., T.G., H.J.F., T.R.M., Departments of Clinical Pharmacology and Neurosciences, Neurodégénératives, UMR 5293, Bordeaux, France.

ACKNOWLEDGMENT
DNA and brain samples: The authors used DNA samples and phenotype data from the NINDS Human Genetics Resource Center DNA and Cell Line Repository at Coriell Institute for Medical Research (Newark, NJ); cc.coriell.org/ninds, and thank the patients and the submitters who contributed samples to this repository. Human tissue was obtained from the Queen Square Brain Bank (London, UK), the Institute of Psychiatry Brain Bank, King's College (London, UK), the UK Parkinson’s disease tissue bank at Imperial College (London, UK), and the Institute of Neurology, London, UK.
Newcastle Brain Tissue Resource at Newcastle University (Newcastle, UK), the Manchester Brain Bank at the University of Manchester (Manchester, UK), Jacksonville Brain Bank for Alzheimer’s, Parkinson’s and Related Disorders at the Mayo Clinic (Jacksonville, FL), the NCICD Brain and Tissue Bank for Developmental Disorders at the University of Maryland (Baltimore, MD), the New York Brain Bank of the Taub Institute at Columbia University (New York, NY), the Human Brain and Spinal Fluid Resource Center (Los Angeles, CA), the Miami Brain Bank (Miami, FL), the Center for Neurodegenerative Disease Research at the University of Pennsylvania (Philadelphia, PA), the Harvard Brain Bank (Boston, MA), the Emory University Alzheimer’s Disease Research Center Brain Bank (Atlanta, GA), Neurobiobank München at the Ludwig-Maximilians-Universität (Munich, Germany), Brain Bank Center Würzburg (Würzburg, Germany), the Netherlands Brain Bank at the Netherlands Institute for Neuroscience (Amsterdam, Netherlands), and the Neurological Tissue Bank at the University of Barcelona (Barcelona, Spain). The Italian samples were obtained from the Parkinson Institute Biobank (parkinsonbiobank.com), member of the Telethon Network of Genetic Biobank (project n. GTB12001) funded by TELETHON Italy, and supported by “Fondazione Giorgio Grassi per il Morbo di Parkinson.”

STUDY FUNDING
No targeted funding reported.

DISCLOSURE
A. Sailer was supported in part by the Intramural Research Program of the National Institutes of Health (National Institute of Neurological Disorders and Stroke, National Institute on Aging; project number: Z01 AG000949). She also received funding support from the Multiple System Atrophy Trust, the Medical Research Council UK, and Wellcome Trust. S. Schulte was supported in part by the Intramural Research Program of the National Institutes of Health (National Institute of Neurological Disorders and Stroke, National Institute on Aging; project number: Z01 AG000949). She also received a R25 career development grant by the National Institute of Neurological Disorders and Stroke (grant number: R25 NS06729) and a Rapid Response Innovation Award by the Michael J. Fox Foundation. M. Nalls was supported in part by the Intramural Research Program of the National Institutes of Health (National Institute on Aging; project number: Z01 AG000949). C. Schulte reports no disclosures relevant to the manuscript. M. Federrath was supported in part by the Intramural Research Program of the National Institutes of Health (National Institute of Neurological Disorders and Stroke, National Institute on Aging; project number: Z01 AG000949). A. Less received funding support from the Multiple System Atrophy Trust, the Medical Research Council UK, Wellcome Trust, and the Reta Lila Weston Institute for Neurological Studies. O. Rossi, D. Dickson, K. Mok, N. Mercacci, L. Schottalmader, and V. Chelbin report no disclosures relevant to the manuscript. H. Ling receives funding from a CBD Solutions Research Grant and is employed by Reta Lila Weston Institute for Neurological Studies. S. O’Sullivan reports no disclosures relevant to the manuscript. N. Wood received funding support from the Multiple System Atrophy Trust, the Medical Research Council UK, Wellcome Trust, and the Reta Lila Weston Institute for Neurological Studies. B. Traynor was supported in part by the Intramural Research Program of the National Institutes of Health (National Institute on Aging; project number: Z01 AG000949). L. Ferrucci was supported in part by the Intramural Research Program of the National Institutes of Health (National Institute of Neurological Disorders and Stroke, National Institute on Aging; project number: Z01 AG000949). H. Federrath reports no disclosures relevant to the manuscript. T. Miyake reports no disclosures relevant to the manuscript. H. Morris reports grants from Parkinson’s UK and Medical Research Council UK during the conduct of the study and grants from Welsh Assembly Government, personal fees from Teva, personal fees from ABV, personal fees from Teva, personal fees from UCB, personal fees from Boehringer-Ingelheim, personal fees from GSK, nonfinancial support from Teva, grants from Ipsen Fund, nonfinancial support from Medtronic, grants from MND Association, grants from PSP Association, grants from CBD Solutions, grants from Drake Foundation, and personal fees from Acorda, outside the submitted work; in addition, Dr. Morris has a patent related to C9ORF72. H. R. M. is a co-applicant on a patent application related to C9ORF72: Method for diagnosing a neurodegenerative disease (PCT/ GB2012/052140) pending. G. Deuschl, N. Quinn, H. Widner, A. Alba- nova, J. Infante, K. Bhatia, and W. Prowse report no disclosures relevant to the manuscript. W. Oertel has served as a consultant for Mundipharma, Novartis, and UCB Pharma; on advisory boards for Boehringer Ingelheim, Merck, Sharp & Dohme, Medtronic, Mundipharma, Neuraport, Novartis, UCB Pharma, and Teva; and received honoraria for presenting lectures from Abbvie, Destinix, Boehringer Ingelheim, Mundipharma, Novartis, Orion Pharma, Schwarz Pharma Neuroscience/UCB, and Teva. He has received scientific grants from the German Ministry of Education and Health, the German Research Foundation, the Charitable University Founda- tion, the Internal Parkinson Fonds, the Michael J. Fox Foundation, and Novartis Pharma Germany, and holds shares in Merck, Medigene, and Roche. G. Hoglinger has served on the advisory boards for Abbvie, Asce- neuron, Bristol-Myers Squibb, Roche, Sillas, and UCB and has received honor- aria for scientific presentations from Abbvie, Roche, and UCB; has received research support from CurePSP, the International Parkinson Fonds, the German Academic Exchange Service (DAAD), German Research Foundation (DFG) and the German Ministry of Education and Research (BMBF), and the Sillas Life Sciences Group; and has received institutional support from the German Center for Neurodegenerative Dis- eases (DZNE). U. Wüllner, S. Goldwurm, M. Pellecchia, J. Ferreira, E. Tolosa, B. Bloom, O. Rascol, and W. Messier report no disclosures relevant to the manuscript. A. Singleton was supported in part by the Intramural Research Program of the National Institutes of Health (National Institute on Aging; project number: Z01 AG000949). H. Houlden received funding support from the Multiple System Atrophy Trust, the Medical Research Council UK, and Wellcome Trust. T. Revesz received funding support from the Multiple System Atrophy Trust, the Medical Research Council UK, Wellcome Trust, and the Reta Lila Weston Institute for Neurological Studies. J. Holton received funding support from the Multiple System Atrophy Trust, the Medical Research Council UK, Wellcome Trust, and the Reta Lila Weston Institute for Neurological Studies. T. Gasser and G. Wenning report no disclosures relevant to the manuscript. A. Singleton was supported in part by the Intramural Research Program of the National Institutes of Health (National Institute on Aging; project number: Z01 AG000949). H. Houlden received funding support from the Multiple System Atrophy Trust, the Medical Research Council UK, the Michael J. Fox Foundation, Wellcome Trust, and the Reta Lila Weston Institute for Neurological Studies. Go to Neurology.org for full disclosures.

Received January 17, 2016. Accepted in final form June 15, 2016.

REFERENCES
1. Hata K, Momose Y, Tokiguchi S, et al. Multiplex families with multiple system atrophy. Arch Neurol 2007;64:545–551.
2. Soma H, Yabe I, Takeri A, Fujiki N, Yanagihara T, Sasaki H. Heredity in multiple system atrophy. J Neurol Sci 2006;240:107–110.
3. Wullner U, Schmitt I, Kammal M, Krätzschmar HA, Neumann M. Definite multiple system atrophy in a German family. J Neurol Neurosurg Psychiatry 2009;80:449–450.
4. Vidal JS, Vidalhelt M, Derkinderen P, Tzourio C, Alperovich A. Familial aggregation in atypical Parkinson’s disease; a case control study in multiple system atrophy and progressive supranuclear palsy. J Neurol 2010;257:1388–1393.

Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H, Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 1998;249:180–182.
5. Galvin JE, Lee VM, Trojanowski JQ. Synucleinopathies: clinical and pathological implications. Arch Neurol 2001;58:186–190.
6. Simon-Sanchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet 2009;19:15.
8. Scholz SW, Houlden H, Schulte C, et al. SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol 2009;65:610–614.

9. Vilaino-Guell C, Soto-Orobtaza Al, Rajput A, et al. MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy. Neurology 2011;76:670–672.

10. Multiple-System Atrophy Research Collaboration. Mutations in COQ2 in familial and sporadic multiple-system atrophy. N Engl J Med 2013;369:233–244.

11. Sharma M, Wenning G, Kruger R; European Multiple-System Atrophy Study Group. Mutant COQ2 in multiple system atrophy. N Engl J Med 2014;371:80–88.

12. Schottlander LV, Houlden H; Multiple-System Atrophy Brain Bank Collaboration. Mutant COQ2 in multiple-system atrophy. N Engl J Med 2014;371:81.

13. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71:670–676.

14. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447:661–678.

15. Ferrucci L, Bandinelli S, Benvenuti E, et al. Subsystems contributing to the decline in ability to walk: bridging the gap between epidemiology and geriatric practice in the InCHIANTI study. J Am Geriatr Soc 2000;48:1618–1625.

16. Chiu A, Schymick JC, Restauro G, et al. A two-stage genome-wide association study of sporadic amyotrophic lateral sclerosis. Hum Mol Genet 2009;18:1524–1532.

17. Fedorenko V, Price TR, Sailer A, et al. Genome-wide estimate of the heritability of multiple system atrophy. Parkinsonism Relat Disord 2016;22:35–41.

18. Li Y, Willer C, Sanna S, Abecasis G. Genotype imputation. Annu Rev Genomics Hum Genet 2009;10:387–406.

19. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 2010;34:816–834.

20. Gibbs JR, van der Brug MP, Hernandez DG, et al. Abundant quantitative trait loci exist for DNA methylation and gene expression in human brain. PLoS Genet 2010;6:e1000952.

21. Nalls MA, Parkratt N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat Genet 2014;46:989–993.

22. Al-Chalabi A, Durr A, Wood NW, et al. Generic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy. PLoS One 2009;4:e7114.

23. Ross OA, Vilaino-Guell C, Wiszek ZK, Farrer MJ, Dickson DW. Reply to: SNCA variants are associated with increased risk of multiple system atrophy. Ann Neurol 2010;67:414–415.

24. Hoglinger GU, Melhem NM, Dickson DW, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 2011;43:699–705.

25. Hollingworth P, Harold D, Sims R, et al. Common variants at ABCA7, MS4A6A/MS4A A1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet 2011;43:429–435.

26. Arinami T, Isikawa M, Inoue A, et al. Chromosomal assignments of the human endothelin family genes: the endothelin-1 gene (EDN1) to 6p23-p24, the endothelin-2 gene (EDN2) to 1p34, and the endothelin-3 gene (EDN3) to 20q13.2-q13.3. Am J Hum Genet 1991;48:990–996.

27. MacCumber MW, Ross CA, Snyder SH. Endothelin in brain: receptors, mitogenesis, and biosynthesis in glial cells. Proc Natl Acad Sci USA 1990;87:2359–2363.

28. Leonard AE, Pereira SL, Sprecher H, Huang YS. Elongation of long-chain fatty acids. Prog Lipid Res 2004;43:36–54.

29. Janssen RJ, Distelmaier F, Smeets R, et al. Contiguous gene deletion of ELOVL7, ERCC8 and NDUFAP2 in a patient with a fatal multisystem disorder. Hum Mol Genet 2009;18:3365–3374.

30. Simon-Kayser B, Scoul C, Renaudin K, et al. Molecular cloning and characterization of FBXO47, a novel gene containing an F-box domain, located in the 17q12 band deleted in papillary renal cell carcinoma. Genes Chromosomes Cancer 2005;43:83–94.

31. Deger JM, Gerson JE, Kayed R. The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration. Aging Cell 2015;14:715–724.

32. Yun JY, Lee WW, Lee JY, Kim HJ, Park SS, Jeon BS. SNCA variants and multiple system atrophy. Ann Neurol 2010;67:554–555.

33. International HapMap Consortium. A haplotype map of the human genome. Nature 2005;437:1299–1320.

34. Concannon C, Lahue RS. The 26S proteasome drives tri-nucleotide repeat expansions. Nucleic Acids Res 2013;41:6098–6108.

35. Kim HJ, Jeon BS, Shin J, et al. Should genetic testing for SCAs be included in the diagnostic workup for MSA? Neurology 2014;83:1733–1738.

36. Lin IS, Wu RM, Lee-Chen GJ, Shan DE, Gwinn-Hardy K. The SCA17 phenotype can include features of MSA-C, PSP and cognitive impairment. Parkinsonism Relat Disord 2007;13:246–249.

37. Martin I, Kim JW, Lee BD, et al. Ribosomal protein s15 gene deletion of ELOVL7, ERCC8 and NDUFAP2 in a patient with a fatal multisystem disorder. Hum Mol Genet 2009;18:3365–3374.

38. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996;273:1516–1517.

39. International Parkinson Disease Genomics Consortium, Nalls MA, Plagnol V, Hernandez DG, et al. Imputation of sequence variants for identification of genetic risks for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet 2011;377:641–649.

40. Koga S, Aoki N, Uriti RJ, et al. When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients. Neurology 2015;85:404–412.
A genome-wide association study in multiple system atrophy
Anna Sailer, Sonja W. Scholz, Michael A. Nalls, et al.

Neurology 2016;87;1591-1598 Published Online before print September 14, 2016
DOI 10.1212/WNL.0000000000003221

This information is current as of September 14, 2016
